Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1707 in MCI due to AD and Mild AD
NCT06114745Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Dose level 1 SHR-1707 with Dose level 1 Placebo (2 arms). Primary endpoints: Adverse events at week 26, Change in vital signs at week 26 and 4 more. Started Apr 2024; status: completed.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06114745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114745.